Susana Lopes-da-Silva1, Luiz Vicente Rizzo. 1. Serviço de Imunoalergologia, Hospital de Santa Maria, Unidade de Imunologia Clínica, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisbon, Portugal. slopessilva@hsm.min-saude.pt
Abstract
BACKGROUND: Autoimmunity has been increasingly recognized as a major issue in patients with common variable immunodeficiency (CVID), the most common symptomatic primary immunodeficiency in adulthood. Different authors report high prevalences of autoimmune diseases in CVID, and several mechanisms have been proposed to explain this apparent paradox. Genetic predisposition, under current surveillance, innate and adaptive immunity deficiencies leading to persistent/recurrent infections, variable degrees of immune dysregulation, and possible failure in central and peripheral mechanisms of tolerance induction or maintenance may all contribute to increased autoimmunity. CONCLUSIONS: Data on the clinical/immunological profile of affected patients and treatment are available mostly concerning autoimmune cytopenias, the most common autoimmune diseases in CVID. Treatment is based on conventional alternatives, in association with short experience with new agents, including rituximab and infliximab. Benefits of early immunoglobulin substitutive treatment and hypothetical premature predictors of autoimmunity are discussed as potential improvements to CVID patients' follow-up.
BACKGROUND:Autoimmunity has been increasingly recognized as a major issue in patients with common variable immunodeficiency (CVID), the most common symptomatic primary immunodeficiency in adulthood. Different authors report high prevalences of autoimmune diseases in CVID, and several mechanisms have been proposed to explain this apparent paradox. Genetic predisposition, under current surveillance, innate and adaptive immunity deficiencies leading to persistent/recurrent infections, variable degrees of immune dysregulation, and possible failure in central and peripheral mechanisms of tolerance induction or maintenance may all contribute to increased autoimmunity. CONCLUSIONS: Data on the clinical/immunological profile of affected patients and treatment are available mostly concerning autoimmune cytopenias, the most common autoimmune diseases in CVID. Treatment is based on conventional alternatives, in association with short experience with new agents, including rituximab and infliximab. Benefits of early immunoglobulin substitutive treatment and hypothetical premature predictors of autoimmunity are discussed as potential improvements to CVIDpatients' follow-up.
Authors: B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler Journal: J Clin Immunol Date: 2003-09 Impact factor: 8.317
Authors: Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg Journal: J Clin Invest Date: 2010-03-08 Impact factor: 14.808
Authors: Saul Oswaldo Lugo Reyes; Guadalupe Ramirez-Vazquez; Alonso Cruz Hernández; Edgar A Medina-Torres; Ana Belen Ramirez-Lopez; Corín España-Cabrera; Citlali A Hernandez-Lopez; Marco A Yamazaki-Nakashimada; Francisco J Espinosa-Rosales; Sara E Espinosa-Padilla; Chiharu Murata Journal: J Clin Immunol Date: 2015-12-28 Impact factor: 8.317
Authors: Rita R Barbosa; Sara P Silva; Susana L Silva; Alcinda Campos Melo; Elisa Pedro; Manuel P Barbosa; M Conceição Pereira-Santos; Rui M M Victorino; Ana E Sousa Journal: PLoS One Date: 2011-08-03 Impact factor: 3.240
Authors: Karina M Melo; Karina I Carvalho; Fernanda R Bruno; Lishomwa C Ndhlovu; Wassim M Ballan; Douglas F Nixon; Esper G Kallas; Beatriz T Costa-Carvalho Journal: PLoS One Date: 2009-07-29 Impact factor: 3.240